High FBXW7 expression is associated with a “hot” tumor microenvironment, which exhibits a more favorable response to PD-1 blockade therapy, highlighting FBXW7 as a potential biomarker for immunotherapy efficacy (33) (Figure 2). The gene discussed is PDCD1; the disease is neoplasm.